The meeting brings together a unique and international mix of large and

medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs,

CROs, emerging companies and tool providers.

BioPorto will be presenting NGAL as the biomarker for acute renal injury in discovery research, pre-clinical and clinical studies of drugs in the

pharmaceutical industry. NGAL has shown a great potential as a safety biomarker in renal toxicity associated issues and is proposed by many to

be the main tool for renal safety assessment of drugs. If you would like to meet us and set up an appointment, please contact Jakob Ohm Eriksen

at joe@bioporto.com